{"id":"NCT02167139","sponsor":"Samsung Bioepis Co., Ltd.","briefTitle":"A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy","officialTitle":"A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Immunogenicity of SB5 Compared to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-05","primaryCompletion":"2015-04","completion":"2015-10","firstPosted":"2014-06-18","resultsPosted":"2017-01-19","lastUpdate":"2017-08-17"},"enrollment":544,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Humira (adalimumab)","otherNames":[]},{"type":"DRUG","name":"SB5 (proposed biosimilar to adalimumab)","otherNames":[]}],"arms":[{"label":"SB5 (proposed biosimilar to adalimumab)","type":"EXPERIMENTAL"},{"label":"Humira (adalimumab)","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomised, double-blind, parallel group, multicentre clinical study to evaluate the efficacy, safety, tolerability, pharmacokinetics and immunogenicity of SB5 compared to Humira® in subjects with moderate to severe RA despite MTX therapy.","primaryOutcome":{"measure":"American College of Rheumatology 20% Response Criteria (ACR20)","timeFrame":"Week 24","effectByArm":[{"arm":"SB5 (Proposed Biosimilar to Adalimumab)","deltaMin":72.4,"sd":null},{"arm":"Humira (Adalimumab)","deltaMin":72.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":2,"countries":["Lithuania","Poland"]},"refs":{"pmids":["33263165","32468892","31958281","29439289","28950421"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":268},"commonTop":["Nasopharyngitis","Headache"]}}